

Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and applicable state and/or federal laws.

Quantitative Electroencephalogram (qEEG) and Referenced Electroencephalogram (rEEG)

MP9622

Covered Service: Yes

Prior Authorization Required: No

Additional Information: None

Prevea360 Health Plan Medical Policy:

- 1.0 Quantitative electroencephalogram (qEEG; brain mapping) **does not** require prior authorization and is considered medically necessary for **ANY** of the following:
- 1.1 Evaluation of epilepsy when used for:
 - 1.1.1 Identification of epileptic spikes or seizures in members requiring long-term EEG monitoring
 - 1.1.2 Pre-surgical evaluation in members with intractable epilepsy
 - 1.1.3 Monitoring for possible seizures in high-risk members in the intensive care unit (ICU)
 - 1.2 Monitoring for early detection of acute, intracranial surgery-related complications in the operating room or intensive care unit (ICU).
 - 1.3 Evaluation of members symptomatic for possible cerebrovascular disease when neuroimaging and standard EEG analysis remain inconclusive.
 - 1.4 Evaluation of encephalopathy when diagnosis is unresolved after initial clinical evaluation.
 - 1.5 Evaluation of dementia (e.g., Alzheimer's or Parkinson's related) when diagnosis is unresolved after initial clinical evaluation.
 - 1.6 qEEG is considered experimental and investigational, and therefore not medically necessary for all other indications, including but not limited to:
 - 1.6.1 Alcoholism
 - 1.6.2 Attention disorders
 - 1.6.3 Autism spectrum disorders/pervasive developmental disorders
 - 1.6.4 Depression
 - 1.6.5 Drug abuse

Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and applicable state and/or federal laws.

- 1.6.6 Learning disabilities
- 1.6.7 Mild or moderate head injury
- 1.6.8 Post-concussion syndrome
- 1.6.9 Prediction of pharmacotherapy response to psychotropic medication
- 1.6.10 Schizophrenia

	Committee/Source	Date(s)
Document		
Created:	Medical Policy Committee/Health Services Division	January 18, 2023
Revised:	Medical Policy Committee/Health Services Division	January 17, 2024
Reviewed:	Medical Policy Committee/Health Services Division	January 17, 2024

Published: 02/01/2024

Effective: 02/01/2024